ArticleMedical oncology (Northwood, London, England)2014
Pentraxin-3 as a prognostic marker in patients with small-cell lung cancer.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- PTX3 facilitates tumor cell migration and invasion through the miR-1255b-2-3p/CYP2J2 axis in oral squamous cell carcinoma.Cancer cell international · 2026Article
- The long pentraxin 3: the invisible loom weaving the warp and weft of tumor destiny.Frontiers in immunology · 2025Review
- Prognostic Value of Pentraxin3 Protein Expression in Human Malignancies: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- Insights into the Relationship between Pentraxin-3 and Cancer.International journal of molecular sciences · 2022Review
- PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.CNS neuroscience & therapeutics · 2022Article
- Promoting role of pentraxin-3 in esophageal squamous cell carcinoma.Molecular therapy oncolytics · 2022Article
- Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a Lung Cancer Biomarker.Disease markers · 2020Article
- Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects.OncoTargets and therapy · 2020Review
- The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer.Frontiers in immunology · 2019Review
- Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.International journal of cancer · 2017Article
- Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo.Journal of neuro-oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine the incidence and role of pentraxin-3 (PTX-3) overexpression as a predictive/prognostic marker in small-cell lung carcinoma (SCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of SCLC. A chart review for demographic and clinical data was performed on patients with SCLC diagnosed between 2005 and 2008. PTX-3 overexpression was evaluated using immunohistochemistry performed on archival paraffin-embedded specimens. 125 patients with SCLC were identified (23 females, 102 males; median age 62.91±8.55 years, range 37-82) all of whom had adequate tissue specimens available for PTX-3 testing. High PTX-3 expression was detected in 25.6% SCLCs and was significantly associated with male gender and smokers. Moreover, elevated PTX-3 levels were correlated with reduced overall (OS) and disease-free survival, and were an independent negative prognostic factor for OS in SCLC. Our findings suggest that high PTX-3 expression appeared to correlate with aggressive behavior in SCLC, and it may be a useful prognostic marker for SCLC patients and a potential molecular target for SCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.